Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T17:10:45.024Z.
Calculation as of: 2026-10-06T17:10:45.024Z.
Quote observation: 2026-10-06T17:10:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 236ecad6846b0cc00793ea2ceb9f38c60eee5e96b58175726d9ae7432cdeb63e
EARNINGS YIELD
N/A
Market Cap
$668.31M
Earnings Yield
0.87%
TTM Avg
4.56%
3Y Avg
4.76%
5Y Avg
4.76%
Market Cap
$662.86M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$695.04M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$703.33M
Earnings Yield
N/A
TTM Avg
0.35%
3Y Avg
0.35%
5Y Avg
0.35%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Annexon, Inc. (ANNX) | $674.47M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $671.91M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $668.31M | 0.87% | 4.56% | 4.76% | 4.76% |
| Solid Biosciences Inc. (SLDB)vs › | $681.76M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $662.86M | N/A | N/A | N/A | N/A |
| Starling Oncology, Inc. (STLN)vs › | $657.92M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $695.04M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $647.90M | N/A | N/A | N/A | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $703.33M | N/A | 0.35% | 0.35% | 0.35% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $703.58M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
